Home » Stocks » BTX

Brooklyn ImmunoTherapeutics, Inc. (BTX)

Stock Price: $10.62 USD 0.36 (3.51%)
Updated Jul 26, 2021 4:00 PM EDT - Market closed
Market Cap 541.09M
Revenue (ttm) 3.41M
Net Income (ttm) -20.92M
Shares Out 51.73M
EPS (ttm) -2.80
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 26
Last Price $10.62
Previous Close $10.26
Change ($) 0.36
Change (%) 3.51%
Day's Open 10.27
Day's Range 10.03 - 10.86
Day's Volume 858,224
52-Week Range 3.04 - 80.67

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Acquisition Advances Transformation Into Platform Company Focused on Cell, Gene Editing and Cytokine Therapy

1 week ago - GlobeNewsWire

NEW YORK, July 13, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/...

1 week ago - GlobeNewsWire

NEW YORK, July 12, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics LLC (NYSE American: BTX) (“Brooklyn” or “the Company”), a biopharmaceutical company focused on exploring the role that cytokine an...

2 weeks ago - GlobeNewsWire

Pharma stocks like MNMD stock and ANVS stock offer investors long-term growth potential in a market on track to hit a value of $1.70 trillion. The post 7 Top-Rated Pharmaceutical Companies to Invest In ...

Other stocks mentioned: ANVS, CTXR, JAZZ, MNMD, SAVA, SWTX
2 weeks ago - InvestorPlace

NEW YORK, July 06, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics LLC (NYSE American: BTX) (“Brooklyn” or “the Company”), a biopharmaceutical company focused on exploring the role that cytokine an...

2 weeks ago - GlobeNewsWire

Looking to roll the dice? Consider buying one (or more) of these seven high-risk, but possibly high-return, Reddit stocks.

Other stocks mentioned: AHT, GEO, PUBM, SKLZ, SNDL, WISH
1 month ago - InvestorPlace

The biotech is bulking up with a new acquisition.

1 month ago - The Motley Fool

Brooklyn ImmunoTherapeutics LLC (NYSE: BTX) has executed a non-binding letter of intent to acquire Novellus Therapeutics, a company developing engineered mesenchymal stem cell (MSC) therapies using mRNA...

1 month ago - Benzinga

Novellus Therapeutics develops next-generation mesenchymal stem cell products using licensed patented mRNA cell reprogramming and gene editing technologies Novellus Therapeutics develops next-generation...

1 month ago - GlobeNewsWire

BROOKLYN, N.Y., June 09, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene ed...

1 month ago - GlobeNewsWire

BROOKLYN, N.Y., June 08, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene ed...

1 month ago - GlobeNewsWire

BTX stock holders will certainly want to brace for volatility. Still, the outlook's bullish as the company pursues its game-changing research.

1 month ago - InvestorPlace

BROOKLYN, N.Y.--(BUSINESS WIRE)--Brooklyn ImmunoTherapeutics CEO Howard J. Federoff Provides Roadmap for the Company's Future During May 25, 2021 Shareholder Update Call

2 months ago - Business Wire

BROOKLYN, N.Y.--(BUSINESS WIRE)--Brooklyn ImmunoTherapeutics Strengthens Investment in Licensed mRNA Technology Platform with $20M Financing

2 months ago - Business Wire

BROOKLYN, N.Y.--(BUSINESS WIRE)--Michael Andreeff, M.D., Ph.D to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics, Inc.

2 months ago - Business Wire

Is change at the C-suite level a good thing for a company? The facts seem to indicate that it's a positive development for BTX stock holders.

2 months ago - InvestorPlace

BROOKLYN, N.Y.--(BUSINESS WIRE)--Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call Tuesday May 25, 2021 at 4:30 PM ET

2 months ago - Business Wire

BROOKLYN, N.Y.--(BUSINESS WIRE)--Brooklyn ImmunoTherapeutics announces the appointment of Christopher Rohde, Ph.D. to the Company's Scientific Advisory Board

2 months ago - Business Wire

Brooklyn ImmunoTherapeutics Inc (NYSE: BTX) has announced a publication in Breast Cancer Research, which demonstrates how multiplex immunofluorescence (mIF) may be used to characterize the immunological...

2 months ago - Benzinga

BROOKLYN, N.Y.--(BUSINESS WIRE)--Brooklyn ImmunoTherapeutics Announces Publication of Results of IRX-2 Monotherapy in Early Stage Breast Cancer in Breast Cancer Research

2 months ago - Business Wire

This clinical-stage biotech was one of April's brightest stars.

2 months ago - The Motley Fool

BROOKLYN, N.Y.--(BUSINESS WIRE)--Brooklyn ImmunoTherapeutics appoints Erich Mohr, Ph.D., ICD.D. to Board of Directors

2 months ago - Business Wire

An unknown biotech has turned its early investors into millionaires over the past month. Can it continue its momentum?

2 months ago - The Motley Fool

Brooklyn ImmunoTherapeutics Inc (NYSE:BTX) is moving higher again on Monday morning as the stock continues to increase in popularity on the subreddit r/wallstreetbets. What Happened: The stock has soare...

2 months ago - Benzinga

Brooklyn Immuno Therapeutics Inc. (NYSE: BTX) shares are soaring Friday. The stock is likely continuing its run after the company paid $1 million towards the acquisition of a license for Factor Bioscien...

2 months ago - Benzinga

Today, investors in BTX stock appear to be on board in a big way with a major announcement from this hot meme stock and Reddit favorite. The post BTX Stock: The Big News That Has Brooklyn ImmunoTherapeu...

2 months ago - InvestorPlace

Shares of Brooklyn ImmunoTherapeutics have surged more than 800% over the past month despite a lack of a major catalyst that could explain the price jump on a fundamental basis.

2 months ago - Forbes

BROOKLYN, N.Y.--(BUSINESS WIRE)--Brooklyn Acquires License for mRNA Technology Platform to Develop Genetically Edited Cells to Treat Multiple Cancers, Blood and Other Disorders

2 months ago - Business Wire

BROOKLYN, N.Y.--(BUSINESS WIRE)--Brooklyn ImmunoTherapeutics announces the appointment of Matthew During, M.D., Ph.D. to the Company's Scientific Advisory Board

3 months ago - Business Wire

BROOKLYN, N.Y.--(BUSINESS WIRE)--Brooklyn ImmunoTherapeutics Reports Inducement Grants

3 months ago - Business Wire

BROOKLYN, N.Y.--(BUSINESS WIRE)--Brooklyn ImmunoTherapeutics Pays $1 Million Towards Acquisition of License for mRNA Technology Platform to Develop Genetically Edited Cells

3 months ago - Business Wire

BROOKLYN, N.Y.--(BUSINESS WIRE)--Brooklyn ImmunoTherapeutics announces the appointment of Dennis H. Langer to the Company's Board as an independent Director

3 months ago - Business Wire

BTX stock is building on the hype of its recent reverse merger as the company announces its new CEO selection. The post BTX Stock: The Big News That Has Brooklyn ImmunoTherapeutics Racing Higher appeare...

3 months ago - InvestorPlace

BROOKLYN, N.Y.--(BUSINESS WIRE)--Brooklyn ImmunoTherapeutics, Inc. announces the appointment of Howard J. Federoff, M.D., Ph.D., as Chief Executive Officer

3 months ago - Business Wire

Investors getting ready for another busy day of trading need to make sure they know the biggest pre-market stock movers before markets open. The post Today's Biggest Pre-Market Stock Movers: 10 Top Gain...

Other stocks mentioned: ACY, CARA, EEIQ, FHS, PSAC, VBLT, WEI ...
3 months ago - InvestorPlace

BROOKLYN, N.Y.--(BUSINESS WIRE)--Brooklyn ImmunoTherapeutics Completes Reverse Merger with NTN Buzztime

4 months ago - Business Wire

CARLSBAD, Calif., March 23, 2021 /PRNewswire/ -- NTN Buzztime, Inc. (NYSE American: NTN) today announced that it plans to effect a one for two reverse stock split of its outstanding shares of common sto...

Other stocks mentioned: NTN
4 months ago - PRNewsWire

CARLSBAD, Calif., March 15, 2021 /PRNewswire/ -- NTN Buzztime, Inc. (NYSE American: NTN) today announced that its stockholders have approved the proposed merger between NTN and Brooklyn ImmunoTherapeuti...

Other stocks mentioned: NTN
4 months ago - PRNewsWire

CARLSBAD, Calif., March 8, 2021 /PRNewswire/ -- NTN Buzztime, Inc. (NYSE American: NTN) today announced that leading independent proxy advisory firm Institutional Shareholder Services, Inc. ("ISS") reco...

Other stocks mentioned: NTN
4 months ago - PRNewsWire

Ault Global Holdings, Inc (NYSE: DPW) acquired a 9.96% stake in NTN Buzztime, Inc (NYSE: NTN) for $1.01 million or $3.42 per share as of January 29. The purchase price signifies a 37.9% discount to NTN'...

Other stocks mentioned: NTN
5 months ago - Benzinga

CARLSBAD, Calif., Feb. 3, 2021 /PRNewswire/ -- NTN Buzztime, Inc. (NYSE American: NTN), today announced that its registration statement on Form S-4 relating to the proposed merger involving NTN and Broo...

Other stocks mentioned: NTN
5 months ago - PRNewsWire

CARLSBAD, Calif., Jan. 15, 2021 /PRNewswire/ -- NTN Buzztime, Inc. (NYSE American: NTN), announced it received a letter from the NYSE Regulation stating that it is not in compliance with NYSE American L...

Other stocks mentioned: NTN
6 months ago - PRNewsWire

CARLSBAD, Calif., Nov. 13, 2020 /PRNewswire/ -- NTN Buzztime, Inc. (NYSE American: NTN), reported financial results for the third quarter ended September 30, 2020. "Buzztime is working diligently toward...

Other stocks mentioned: NTN
8 months ago - PRNewsWire

NTN Buzztime (NTN) is in the news Monday after an asset sale announcement with eGames.com Holdings put NTN stock on a wild ride.

Other stocks mentioned: NTN
10 months ago - InvestorPlace

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

Other stocks mentioned: NTN
11 months ago - Business Wire

NEW YORK, Aug. 18, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of NTN Buzztime, Inc.

Other stocks mentioned: NTN
11 months ago - PRNewsWire

NEW YORK--(BUSINESS WIRE)-- #Acquisition--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of NTN Buzztime, ...

Other stocks mentioned: NTN
11 months ago - Business Wire

NEW YORK, Aug. 17, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York Cit...

Other stocks mentioned: NTN
11 months ago - PRNewsWire

NTN Buzztime (NTN) is seeing massive gains for its stock on Thursday after announcing a merger deal with Brooklyn ImmunoTherapeutics LLC. The post NTN Buzztime Stock Soars 181% on Merger Deal appeared f...

Other stocks mentioned: NTN
11 months ago - InvestorPlace

NTN Buzztime (NYSE: NTN) shares are trading higher on Thursday after the company announced that its merger deal with Brooklyn ImminoTherapeutics was approved by shareholders.

Other stocks mentioned: NTN
11 months ago - Benzinga

About BTX

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company is based in Brooklyn, New York.

Industry
Television Broadcasting
Founded
2018
Stock Exchange
NYSEAMERICAN
Ticker Symbol
BTX
Full Company Profile

Financial Performance

In 2020, BTX's revenue was $5.80 million, a decrease of -70.72% compared to the previous year's $19.81 million. Losses were -$4.42 million, 115.7% more than in 2019.

Financial Statements